Cardiovascular Research Market

Ularitide

A synthetic form of urodilatin, the 32-residue renal natriuretic peptide ANP(95-126), developed by Cardiorentis as an intravenous infusion for acute heart failure; the 2,157-patient TRUE-AHF trial found no effect on cardiovascular mortality and no product is approved anywhere.

Natriuretic PeptideAcute Heart FailureVasodilatorUrodilatinNot FDA Approved

Also referenced as: Urodilatin, Ularitide acetate, CDD/ANP-95-126

Public product evidence No certificate records are bound to a tracked Ularitide product page A record counts here only when a vendor publishes a certificate against one of its own tracked Ularitide product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Cardiovascular research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Body systems
Heart · Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
3

Urodilatin, Ularitide acetate, CDD/ANP-95-126

Signal depth
Low

No FDA label signal · 4 trials · 282 PubMed results

Promising

Ularitide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Ularitide has 5 name-matched clinical trials (1 international) (highest phase: Phase 3) and 282 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

🌍 1 international trial
Human data
Phase 3
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Ularitide?

Ularitide is the international nonproprietary name for chemically synthesized urodilatin, a 32-amino-acid natriuretic peptide that the human kidney makes from the same precursor as atrial natriuretic peptide. Urodilatin was isolated in 1988 from 1,000 liters of pooled human urine by Forssmann’s group in Heidelberg, who showed that the main urinary form of the cardiodilatin/ANP family is cardiodilatin-95-126, four residues longer at the N-terminus than circulating alpha-ANP (cardiodilatin-99-126) and therefore most likely processed in the kidney tubules rather than filtered from blood (Schulz-Knappe et al., Klinische Wochenschrift, 1988;66(17):752–759). Its sequence is Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr, with a single disulfide bond between the two cysteines closing the 17-residue ring common to all natriuretic peptides; the N-terminal Thr-Ala-Pro-Arg extension is the only difference from the 28-residue ANP. The molecular formula is C145H234N52O44S3 and the molecular weight about 3,506 Da. The drug substance has been used as ularitide acetate.

Ularitide was developed for more than two decades as an intravenous infusion, first in Germany for postoperative kidney failure and asthma, then for acute decompensated heart failure, where it belongs to the same natriuretic-peptide class as nesiritide and carperitide. The phase 3 TRUE-AHF trial found no effect on cardiovascular mortality in 2017, and no ularitide product has been approved anywhere.

How it works

  • Particulate guanylate cyclase agonist. Like ANP, ularitide binds the natriuretic peptide A receptor, a membrane guanylate cyclase, and raises intracellular cGMP in vascular smooth muscle, the renal tubule and other targets, producing vasodilation, diuresis and natriuresis; urodilatin, secreted by distal tubule cells into the tubular lumen, appears to be the natriuretic peptide that physiologically regulates renal sodium and water handling, while circulating ANP governs the cardiovascular system (Anker et al., European Heart Journal, 2015;36(12):715–723; Hirsch et al., European Journal of Medical Research, 2006;11(10):447–454). In decompensated heart failure patients, infusion raised plasma cGMP significantly above both placebo and baseline between 1 and 12 hours (Mitrovic et al., American Heart Journal, 2005;150(6):1239).
  • Relative resistance to neprilysin. Urodilatin and ANP bind the same receptors with similar affinity, but pure recombinant neutral endopeptidase (EC 3.4.24.11) degraded radiolabeled ANP far faster than radiolabeled urodilatin, a difference attributed to the N-terminal extension and consistent with urodilatin’s greater natriuretic activity (Abassi et al., British Journal of Pharmacology, 1994;113(1):204–208).
  • Very short half-life and non-renal clearance. In 12 healthy volunteers given graded 90-minute infusions, synthetic urodilatin had an apparent volume of distribution of 43.7 L, a total body clearance of 5,383 mL/min and a plasma half-life of 5.57 minutes; less than 1% of the infused peptide was recovered in urine, glomerular filtration rate rose 7%, fractional sodium excretion rose 137% and urine flow rose 46% versus placebo, with the natriuretic effect closely tracking plasma concentration (Carstens et al., Clinical Pharmacology and Therapeutics, 1998;64(1):73–86).
  • Tubular as well as hemodynamic natriuresis. In cirrhotic patients with and without ascites, a low-dose infusion raised urinary sodium excretion by 173 to 219% through greater fluid delivery from the proximal tubule and reduced fractional sodium reabsorption in the distal nephron (Carstens et al., Journal of the American Society of Nephrology, 1998;9(8):1489–1498).

Research status

Early renal and pulmonary studies in Germany. The first clinical work used urodilatin to protect kidney function after transplantation. A sequential phase 2a study compared 51 heart-transplant recipients given a 96-hour infusion with 40 historical controls and reported lower peak creatinine (1.5 versus 2.19 mg/dL) and a lower hemodialysis rate (6 versus 10%) (Hummel et al., The Clinical Investigator, 1992;70(8):674–682). The first randomized, placebo-controlled trial, in 24 heart-transplant patients, did not reduce the incidence of acute renal failure (6 of 12 in each group needed renal replacement) but shortened hemofiltration (44 versus 88 hours) (Brenner et al., European Journal of Medical Research, 1995;1(3):137–143). In 14 patients with oliguric renal failure after cardiac surgery, none of 7 treated patients but 6 of 7 placebo patients required hemofiltration or dialysis (Wiebe et al., European Journal of Medical Research, 1996;1(5):259–265). In 18 clinically stable asthmatics, a 40-minute infusion produced bronchodilation comparable to 1.25 mg of inhaled salbutamol that reversed within 30 minutes (Flüge et al., European Journal of Clinical Investigation, 1995;25(10):728–736). A US phase 2 study of urodilatin with mannitol against nephrotoxicity after allogeneic bone marrow transplantation (NCT00390624) ran from July 2003 to December 2006 without posted results. None of these programs reached a confirmatory trial.

SIRIUS I and II in decompensated heart failure. A double-blind, ascending-dose safety study in 24 patients with decompensated chronic heart failure found that 24-hour infusions lowered pulmonary capillary wedge pressure by 10 and 15 mm Hg at the two higher rates at 6 hours, reduced right atrial pressure and cut NT-proBNP by 40 to 45% at 24 hours, with three transient asymptomatic episodes of hypotension (Mitrovic et al., American Heart Journal, 2005;150(6):1239). SIRIUS II, run by CardioPep Pharma, randomized 221 patients to placebo or ularitide at 7.5, 15 or 30 ng/kg/min for 24 hours. At 6 hours, pulmonary capillary wedge pressure fell significantly at 15 and 30 ng/kg/min, dyspnea scores improved at all three rates, systemic vascular resistance fell and cardiac index rose at the two higher rates, systolic blood pressure fell dose-dependently and serum creatinine was unchanged through day 3; blood pressure decrease and hypotension were the most frequent drug-related adverse events (Mitrovic et al., European Heart Journal, 2006;27(23):2823–2832). A renal analysis of the same trial found that estimated glomerular filtration rate, creatinine and blood urea nitrogen were not impaired during infusion or 2 days of follow-up (Lüss et al., American Heart Journal, 2008;155(6):1012.e1-8).

TRUE-AHF (NCT01661634). Cardiorentis of Zug, Switzerland, took ularitide into phase 3. The pivotal trial randomized 2,157 patients with acute heart failure, enrolled within 12 hours of initial presentation, to a 48-hour infusion of ularitide at 15 ng/kg/min or placebo on top of standard therapy; treatment began a median of 6 hours after the initial clinical evaluation, and blood pressure entry criteria and infusion-rate adjustment rules were built in to limit hypotension (Packer et al., European Journal of Heart Failure, 2017;19(5):673–681). The event-driven trial ran from July 2012 to a primary completion in November 2015. The coprimary endpoints were cardiovascular death over a median 15 months of follow-up and a hierarchical clinical composite of symptoms, in-hospital worsening heart failure and death over the first 48 hours. Cardiovascular death occurred in 236 ularitide patients and 225 placebo patients (21.7 versus 21.0%; hazard ratio 1.03; 96% CI 0.85 to 1.25; P=0.75), and the composite did not differ. Ularitide lowered systolic blood pressure and NT-proBNP more than placebo, but cardiac troponin T changes during the infusion did not differ in the 55% of patients with paired samples, undermining the hypothesis that early vasodilation limits myocardial injury (Packer et al., New England Journal of Medicine, 2017;376(20):1956–1964). The FDA had granted Fast Track designation for acute decompensated heart failure in December 2015, before the results were known. No US new drug application or European marketing authorization application followed.

Meta-analysis. A systematic review of 12 randomized double-blind hemodynamic studies found a large effect of ularitide on pulmonary artery wedge pressure at 6 hours (Hedges’ g −0.979 versus placebo) and a greater pooled effect than other vasoactive agents, but addressed only short-term hemodynamics (Mitrovic et al., ESC Heart Failure, 2018;5(6):1023–1034).

Cirrhotic ascites (NCT04311489). Building on a small Danish crossover study showing a modest natriuretic response in cirrhosis despite activated pressor hormones (Carstens et al., BMC Gastroenterology, 2007;7:1), the University of Aarhus ran a randomized, placebo-controlled phase 2 trial of a 48-hour infusion in refractory ascites. It was terminated after interim analyses showed safety concerns, having randomized 17 patients 2:1 (11 ularitide, 6 placebo). Contrary to the hypothesis, mean urine production fell after 24 hours of ularitide, sodium excretion and weight did not improve, the starting rate of 30 ng/kg/min had to be reduced to 20 for safety, serious blood pressure reductions impaired renal responsiveness, and the incidence rate ratio of adverse reactions versus placebo was 8.5 (95% CI 2 to 35; P=0.003) (Gantzel et al., Hepatology Communications, 2024;8(7):e0481).

Pulmonary arterial hypertension. Cardiorentis AG registered an open-label, dose-escalation phase 2 study of intravenous ularitide on pulmonary hemodynamics in patients with pulmonary arterial hypertension (EU trial 2020-004815-29), authorized by the German competent authority on May 11, 2021. The register lists it as prematurely ended, with a global end-of-trial date of July 15, 2024; a sponsor summary report was posted to the register on December 21, 2024, and no peer-reviewed report is indexed in PubMed. As of November 2026, no ularitide trial is recruiting on ClinicalTrials.gov or the EU register, and no application is pending with any regulator.

Common dosage forms

  • Investigational solution for intravenous infusion. Ularitide acetate as a sterile preparation for continuous intravenous infusion, supplied only to clinical-trial sites in the SIRIUS, TRUE-AHF, ascites and pulmonary hypertension studies.
  • No approved presentation. No ularitide or urodilatin product is authorized in any country, and no oral, subcutaneous, inhaled or compounded presentation exists.

Key considerations

  • Regulatory status. The Research Market status reflects the absence of any FDA-approved or foreign-approved ularitide product and of any active US-directed development program. Drugs@FDA and DailyMed list no ularitide application or label, the December 2015 Fast Track designation was never followed by a filing, and the last registered trial, a European pulmonary hypertension study, ended prematurely in July 2024.
  • Hemodynamic benefit did not translate into outcomes. Ularitide reliably lowers filling pressures, blood pressure and NT-proBNP within hours, yet TRUE-AHF showed neither a mortality effect nor a difference in the 48-hour clinical composite, and troponin release was unchanged, which leaves the early-vasodilator hypothesis in acute heart failure unsupported.
  • Hypotension is the dose-limiting toxicity. Dose-dependent blood pressure falls were the most frequent drug-related adverse events in SIRIUS II, TRUE-AHF needed blood pressure entry criteria and rate-adjustment rules, and in the cirrhosis trial blood pressure reductions were severe enough to blunt the renal response and stop the study, with an eightfold higher rate of adverse reactions than placebo.
  • Not interchangeable with other natriuretic peptides. Ularitide is the renal ANP(95-126) isoform, four residues longer than carperitide (ANP) and unrelated in sequence to nesiritide (BNP); its greater neprilysin resistance and tubular site of action are the pharmacological case for the molecule, but the clinical data for one natriuretic peptide do not transfer to another.